/REPL
REPL Stock - Replimune Group, Inc.
Healthcare|BiotechnologyNASDAQ
$9.88+1.96%
+$0.19 (+1.96%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.4%upside
Target: $13.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for REPL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.78 – $9.98
TARGET (TP)$13.67
STOP LOSS$9.09
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$14.79
52W Low$2.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-4,575,000 | $-4,139,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-261,627,000 | $-234,773,000 | $-177,080,000 | $-121,484,000 | $-82,762,000 |
| Net Income | $-247,297,000 | $-215,794,000 | $-174,284,000 | $-118,036,000 | $-80,870,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 |
Company Overview
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
36%
Hold / Neutral
6
55%
Sell / Underperform
1
9%
Analyst Consensus🔴 Bearish
4 Bullish7 Neutral/Bearish
Price Targets
$12
Average Target
↑ 18.3% Upside
Now
$2
Low
$12
Average
$44
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | BMO Capital Markets | Upgrade | Market Perform | $11 |
| October 27th 2025 | H.C. Wainwright | Upgrade | Buy | $12 |
| October 20th 2025 | Piper Sandler | Upgrade | Overweight | $13 |
| October 20th 2025 | JP Morgan | Upgrade | Neutral | - |
| October 20th 2025 | Leerink Partners | Upgrade | Outperform | $13 |
| October 20th 2025 | Wedbush | Upgrade | Outperform | $18 |
| September 19th 2025 | JP Morgan | Downgrade | Underweight | - |
| July 30th 2025 | Cantor Fitzgerald | Upgrade | Overweight | - |
| July 23rd 2025 | BMO Capital Markets | Downgrade | Underperform | $2 |
| July 23rd 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| July 23rd 2025 | Barclays | Downgrade | Equal Weight | $3 |
| July 22nd 2025 | Leerink Partners | Downgrade | Market Perform | $3 |
| July 22nd 2025 | JP Morgan | Downgrade | Neutral | $9 |
| July 22nd 2025 | Wedbush | Downgrade | Neutral | $4 |
| July 22nd 2025 | Piper Sandler | Downgrade | Neutral | $3 |
Earnings History & Surprises
REPLBeat Rate
39%
Last 18 quarters
Avg Surprise
-2.3%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.90
Q4 2025
EPS Surprise History
Q1 24
+18.1%
$-0.77vs$-0.94
Q2 24
+4.7%
$-0.82vs$-0.86
Q3 24
+11.4%
$-0.78vs$-0.88
Q4 24
+9.3%
$-0.68vs$-0.75
Q1 25
-12.9%
$-0.79vs$-0.70
Q2 25
-9.3%
$-0.82vs$-0.75
Q3 25
-14.5%
$-0.95vs$-0.83
Q4 25
-3.4%
$-0.90vs$-0.87
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 20, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.85 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.87 | $-0.90 | -3.4% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.83 | $-0.95 | -14.5% | ✗ MISS |
Q2 2025 | May 22, 2025 | $-0.75 | $-0.82 | -9.3% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $-0.70 | $-0.79 | -12.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.75 | $-0.68 | +9.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.88 | $-0.78 | +11.4% | ✓ BEAT |
Q2 2024 | May 16, 2024 | $-0.86 | $-0.82 | +4.7% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $-0.94 | $-0.77 | +18.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.80 | $-0.90 | -12.5% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.85 | $-0.75 | +11.8% | ✓ BEAT |
Q2 2023 | May 18, 2023 | $-0.66 | $-0.74 | -12.1% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-0.77 | $-0.69 | +10.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.78 | $-0.79 | -1.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-0.63 | $-0.78 | -23.8% | ✗ MISS |
Q2 2022 | May 19, 2022 | $-0.60 | $-0.60 | 0.0% | = MET |
Q1 2022 | Feb 3, 2022 | $-0.58 | $-0.57 | +1.7% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.55 | $-0.56 | -1.8% | ✗ MISS |
Q3 2021 | Aug 6, 2021 | $-0.45 | $-0.53 | -17.8% | ✗ MISS |
Latest News
Replimune Group shares are trading higher after the company announced it presented biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab.
📈 PositiveBenzinga•Nov 11, 2025, 09:35 PM
Replimune Presents New IGNYTE Trial Data Showing RP1 Plus Nivolumab Reverses Resistance To PD-1 Blockade And Delivers Durable Responses In Advanced Melanoma
📈 PositiveBenzinga•Nov 7, 2025, 09:49 PM
Replimune Group Q2 EPS $(0.90) Misses $(0.74) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 01:21 PM
BMO Capital Upgrades Replimune Group to Market Perform, Raises Price Target to $11
📈 PositiveBenzinga•Nov 3, 2025, 10:37 AM
HC Wainwright & Co. Upgrades Replimune Group to Buy, Announces $12 Price Target
📈 PositiveBenzinga•Oct 27, 2025, 11:21 AM
JP Morgan Upgrades Replimune Group to Neutral, Announces $11 Price Target
➖ NeutralBenzinga•Oct 20, 2025, 10:01 PM
Leerink Partners Upgrades Replimune Group to Outperform, Raises Price Target to $13
📈 PositiveBenzinga•Oct 20, 2025, 02:35 PM
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $18
📈 PositiveBenzinga•Oct 20, 2025, 01:09 PM
Replimune soars 108% on BLA resubmission acceptance of melanoma asset
📈 PositiveSeeking Alpha•Oct 20, 2025, 01:00 PM
Replimune shares are trading higher after the FDA accepted the company's resubmission of the Biologics License Application for RP1 in combination with nivolumab for advanced melanoma, with a PDUFA date of April 10, 2026.
📈 PositiveBenzinga•Oct 20, 2025, 12:55 PM
Market-Moving News for October 20th
➖ NeutralBenzinga•Oct 20, 2025, 11:36 AM•Also: ,
The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivolumab For Advanced Melanoma, PDUFA Date Is April 10, 2026
📈 PositiveBenzinga•Oct 20, 2025, 11:07 AM
Replimune Group Option Alert: Oct 17 $6 Calls Sweep (16) Near The Ask: 1346 @ $0.25 Vs 129 OI
➖ NeutralBenzinga•Sep 29, 2025, 06:27 PM
JP Morgan Downgrades Replimune Group to Underweight
📉 NegativeBenzinga•Sep 19, 2025, 11:39 AM•Also:
Replimune Group shares are trading lower as the company evaluates FDA feedback to determine next steps. A path forward under the accelerated approval pathway has not been determined.
📉 NegativeBenzinga•Sep 18, 2025, 01:23 PM
Replimune Group Completes Type A Meeting With FDA On RP1 BLA For Advanced Melanoma; Path Forward for Accelerated Approval Still Undetermined
➖ NeutralBenzinga•Sep 18, 2025, 01:19 PM
HC Wainwright & Co. Reiterates Neutral on Replimune Groupto Neutral
➖ NeutralBenzinga•Sep 8, 2025, 12:14 PM
Replimune gains as FDA to discuss path for rejected skin cancer drug
📈 PositiveSeeking Alpha•Sep 2, 2025, 07:00 PM
Replimune Schedules Type A Meeting With FDA To Discuss CRL For RP1 Plus Nivolumab
➖ NeutralBenzinga•Sep 2, 2025, 12:03 PM
Replimune down as FDA's top cancer drug regulator reportedly intervened in drug rejection
📉 NegativeSeeking Alpha•Aug 4, 2025, 10:57 AM•Also:
Frequently Asked Questions about REPL
What is REPL's current stock price?
Replimune Group, Inc. (REPL) is currently trading at $9.88 per share. The stock has moved +1.96% today.
What is the analyst price target for REPL?
The average analyst price target for REPL is $13.67, based on 1 analyst.
What sector is Replimune Group, Inc. in?
Replimune Group, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is REPL's market cap?
Replimune Group, Inc. has a market capitalization of $0.77 billion, making it a small-cap company.
Does REPL pay dividends?
No, Replimune Group, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to REPL for comparison